TB Alliance will continue to lead clinical development, while Lupin will leverage its global manufacturing, regulatory, and supply chain expertise to ensure the drug reaches patients worldwide
Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
Over the last two years, Lupin has showcased exceptional improvement in its EcoVadis scoring
Yearbook members are selected basis their S&P Global 2024 Corporate Sustainability Assessment score
This rating reflects Lupin's leadership in environmental transparency and performance
The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
Subscribe To Our Newsletter & Stay Updated
